{
    "info": {
        "nct_id": "NCT06788912",
        "official_title": "KEYMAKER-U01 Substudy 01E: A Phase 2 Umbrella Study With Rolling Arms of Investigational Agents With or Without Chemotherapy in Combination With Pembrolizumab in Treatment of Participants With Newly Diagnosed Resectable Stages II-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)",
        "inclusion_criteria": "* Has previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC)\n* Able to undergo protocol therapy, including necessary surgery\n* Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 as assessed within 10 days before initiation of study intervention.\n* Is able to provide archival or newly obtained core/excisional biopsy of the primary lung tumor or lymph node metastasis.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Has one of the following tumor locations/types: NSCLC involving the superior sulcus, large-cell neuro-endocrine cancer, mixed tumors containing small cell and non-small cell elements, or sarcomatoid tumor.\n* Has Grade ≥2 peripheral neuropathy.\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.\n* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention\n* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.\n* Known additional malignancy that is progressing or has required active treatment within the past 5 years.\n* Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.\n* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid) is allowed.\n* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.\n* Active infection requiring systemic therapy.\n* Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C virus (defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative]) infection.\n* Known history of human immunodeficiency virus (HIV) infection.\n* History of allogeneic tissue/solid organ transplant.",
        "miscellaneous_criteria": "The main inclusion and exclusion criteria include but are not limited to the following:"
    },
    "inclusion_lines": [
        {
            "line": "* Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy",
            "criterions": [
                {
                    "exact_snippets": "Confirmation that epidermal growth factor receptor (EGFR) -directed therapy is not indicated as primary therapy",
                    "criterion": "EGFR-directed therapy indication as primary therapy",
                    "requirements": [
                        {
                            "requirement_type": "indication as primary therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Is able to provide archival or newly obtained core/excisional biopsy of the primary lung tumor or lymph node metastasis.",
            "criterions": [
                {
                    "exact_snippets": "Is able to provide archival or newly obtained core/excisional biopsy of the primary lung tumor or lymph node metastasis.",
                    "criterion": "biopsy of the primary lung tumor or lymph node metastasis",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "archival",
                                "newly obtained"
                            ]
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "core",
                                "excisional"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Able to undergo protocol therapy, including necessary surgery",
            "criterions": [
                {
                    "exact_snippets": "Able to undergo protocol therapy",
                    "criterion": "ability to undergo protocol therapy",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including necessary surgery",
                    "criterion": "ability to undergo necessary surgery",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has previously untreated and pathologically confirmed resectable Stage II, IIIA, or IIIB (N2) non-small cell lung cancer (NSCLC)",
            "criterions": [
                {
                    "exact_snippets": "previously untreated",
                    "criterion": "treatment history",
                    "requirements": [
                        {
                            "requirement_type": "previous treatment",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "pathologically confirmed",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "pathological"
                        }
                    ]
                },
                {
                    "exact_snippets": "resectable",
                    "criterion": "tumor resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Stage II, IIIA, or IIIB (N2)",
                    "criterion": "cancer stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": [
                                "Stage II",
                                "Stage IIIA",
                                "Stage IIIB (N2)"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "non-small cell lung cancer (NSCLC)",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": "non-small cell lung cancer"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1 as assessed within 10 days before initiation of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Has an Eastern Cooperative Oncology Group (ECOG) performance status of either 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": [
                                "0",
                                "1"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "as assessed within 10 days before initiation of study intervention",
                    "criterion": "ECOG performance status assessment timing",
                    "requirements": [
                        {
                            "requirement_type": "assessment timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 10,
                                "unit": "days before initiation of study intervention"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and/or blepharitis, or corneal disease that prevents/delays corneal healing.",
            "criterions": [
                {
                    "exact_snippets": "history of documented severe dry eye syndrome",
                    "criterion": "dry eye syndrome",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of documented severe ... Meibomian gland disease",
                    "criterion": "Meibomian gland disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "history of documented ... blepharitis",
                    "criterion": "blepharitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "corneal disease that prevents/delays corneal healing",
                    "criterion": "corneal disease",
                    "requirements": [
                        {
                            "requirement_type": "effect on corneal healing",
                            "expected_value": [
                                "prevents",
                                "delays"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled, significant cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled, significant ... cerebrovascular disease",
                    "criterion": "cerebrovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history of human immunodeficiency virus (HIV) infection.",
            "criterions": [
                {
                    "exact_snippets": "Known history of human immunodeficiency virus (HIV) infection.",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.",
            "criterions": [
                {
                    "exact_snippets": "History of (noninfectious) pneumonitis/interstitial lung disease that required steroids",
                    "criterion": "history of (noninfectious) pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "has current pneumonitis/interstitial lung disease",
                    "criterion": "current pneumonitis/interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received prior radiotherapy within 2 weeks of start of study intervention, or radiation related toxicities, requiring corticosteroids.",
            "criterions": [
                {
                    "exact_snippets": "Received prior radiotherapy within 2 weeks of start of study intervention",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last radiotherapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "radiation related toxicities, requiring corticosteroids",
                    "criterion": "radiation related toxicities requiring corticosteroids",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid) is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Active autoimmune disease that has required systemic treatment in the past 2 years.",
                    "criterion": "autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid) is allowed.",
                    "criterion": "replacement therapy",
                    "requirements": [
                        {
                            "requirement_type": "allowance",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "examples",
                            "expected_value": [
                                "thyroxine",
                                "insulin",
                                "physiologic corticosteroid"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has Grade ≥2 peripheral neuropathy.",
            "criterions": [
                {
                    "exact_snippets": "Has Grade ≥2 peripheral neuropathy",
                    "criterion": "peripheral neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea).",
            "criterions": [
                {
                    "exact_snippets": "Has active inflammatory bowel disease requiring immunosuppressive medication",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "requiring immunosuppressive medication"
                        }
                    ]
                },
                {
                    "exact_snippets": "previous history of inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis, or chronic diarrhea)",
                    "criterion": "inflammatory bowel disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
            "criterions": [
                {
                    "exact_snippets": "Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention",
                    "criterion": "live or live-attenuated vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days before first dose of study intervention"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent)",
                    "criterion": "chronic systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": ">",
                                "value": 10,
                                "unit": "mg daily of prednisone equivalent"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention",
                    "criterion": "immunosuppressive therapy",
                    "requirements": [
                        {
                            "requirement_type": "current use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to first dose"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients.",
            "criterions": [
                {
                    "exact_snippets": "Severe hypersensitivity (≥Grade 3) to pembrolizumab",
                    "criterion": "hypersensitivity to pembrolizumab",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Severe hypersensitivity (≥Grade 3) to ... any of its excipients",
                    "criterion": "hypersensitivity to pembrolizumab excipients",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "Grade"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Active infection requiring systemic therapy",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "systemic therapy"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known additional malignancy that is progressing or has required active treatment within the past 5 years.",
            "criterions": [
                {
                    "exact_snippets": "Known additional malignancy that is progressing",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "progression status",
                            "expected_value": "progressing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Known additional malignancy that ... has required active treatment within the past 5 years",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or Hepatitis C virus (defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative]) infection.",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "HBsAg reactivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis C virus (defined as detectable hepatitis C virus (HCV) ribonucleic acid (RNA) [qualitative]) infection",
                    "criterion": "Hepatitis C virus infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "detectable HCV RNA (qualitative)",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has one of the following tumor locations/types: NSCLC involving the superior sulcus, large-cell neuro-endocrine cancer, mixed tumors containing small cell and non-small cell elements, or sarcomatoid tumor.",
            "criterions": [
                {
                    "exact_snippets": "Has one of the following tumor locations/types: NSCLC involving the superior sulcus, large-cell neuro-endocrine cancer, mixed tumors containing small cell and non-small cell elements, or sarcomatoid tumor.",
                    "criterion": "tumor location/type",
                    "requirements": [
                        {
                            "requirement_type": "type/location",
                            "expected_value": [
                                "NSCLC involving the superior sulcus",
                                "large-cell neuro-endocrine cancer",
                                "mixed tumors containing small cell and non-small cell elements",
                                "sarcomatoid tumor"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allogeneic tissue/solid organ transplant.",
            "criterions": [
                {
                    "exact_snippets": "History of allogeneic tissue/solid organ transplant.",
                    "criterion": "allogeneic tissue/solid organ transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": [
        {
            "line": "The main inclusion and exclusion criteria include but are not limited to the following:",
            "criterions": []
        }
    ]
}